Arpeggio Bio
YC S19 · Active · Arpeggio Bio develops drugs targeting transcription factors using AI…
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
| AI | Active | YCW20 | |
| Other | Active | YCS19 | |
| AI | Active | YCW20 | |
| AI | Active | YCW20 | |
| AI | Active | YCS21 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
| Other | Active | YCS21 | |
| AI | Active | YCF25 | |
| AI | Inactive | YCW23 | |
| AI | Active | YCW15 | |
| AI | Active | YCW22 |
Also from S19 in AI
All of S19About Arpeggio Bio
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
- YC batch
- S19 · Summer 2019
- Status, per YC
- Active
- Category
- AI
- Team size
- 20
- Location
- Boulder, CO, USA
- Checked
- 36m ago
YC tags: Biotech, Genomics, Drug discovery
Arpeggio Bio: questions
Which YC batch was Arpeggio Bio in?
Arpeggio Bio was in Y Combinator's Summer 2019 batch (S19).
Is Arpeggio Bio still active?
Y Combinator lists Arpeggio Bio as active.
Where is Arpeggio Bio based?
Arpeggio Bio lists Boulder, CO, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.